S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
WARNING: Do You Invest with these Banks (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
WARNING: Do You Invest with these Banks (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
WARNING: Do You Invest with these Banks (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
WARNING: Do You Invest with these Banks (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
OTCMKTS:MRVFF

Nuvo Pharmaceuticals (MRVFF) Stock Forecast, Price & News

$0.98
0.00 (0.00%)
(As of 03/16/2023)
Compare
Today's Range
$0.98
$0.98
50-Day Range
$0.98
$0.98
52-Week Range
$0.42
$1.25
Volume
N/A
Average Volume
11,250 shs
Market Capitalization
$11.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MRVFF stock logo

About Nuvo Pharmaceuticals (OTCMKTS:MRVFF) Stock

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Receive MRVFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRVFF Stock News Headlines

MRVFF Nuvo Pharmaceuticals Inc.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Miravo Healthcare™ Special Meeting Reminder
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Nuvo Pharmaceuticals; reports Q4 results
Miravo Healthcare™ Named to 2022 OTCQX Best 50
See More Headlines
Receive MRVFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRVFF Company Calendar

Today
5/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MRVFF
CIK
N/A
Employees
100
Year Founded
N/A

Profitability

Net Income
$-25,700,000.00
Pretax Margin
25.58%

Debt

Sales & Book Value

Annual Sales
$54.98 million
Cash Flow
$0.09 per share
Book Value
($0.80) per share

Miscellaneous

Free Float
10,602,000
Market Cap
$11.17 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Jesse F. Ledger
    President & Chief Executive Officer
  • Bernard Chiasson
    Chief Scientific Officer & VP-Operations
  • Mary-Jane E. Burkett
    Chief Financial Officer & Vice President
  • Wade Hull
    Vice President-Research & Development
  • Katina K. Loucaides
    Secretary, Vice President & General Counsel













MRVFF Stock - Frequently Asked Questions

How have MRVFF shares performed in 2023?

Nuvo Pharmaceuticals' stock was trading at $0.9443 at the beginning of the year. Since then, MRVFF stock has increased by 3.7% and is now trading at $0.9795.
View the best growth stocks for 2023 here
.

What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the OTCMKTS under the ticker symbol "MRVFF."

How do I buy shares of Nuvo Pharmaceuticals?

Shares of MRVFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvo Pharmaceuticals' stock price today?

One share of MRVFF stock can currently be purchased for approximately $0.98.

How much money does Nuvo Pharmaceuticals make?

Nuvo Pharmaceuticals (OTCMKTS:MRVFF) has a market capitalization of $11.17 million and generates $54.98 million in revenue each year. The company earns $-25,700,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 6733 MISSISSAUGA ROAD SUITE 800, MISSISSAUGA A6, L5N 6J5. The official website for the company is www.nuvopharmaceuticals.com. The company can be reached via phone at (905) 673-6980, via email at ir@nuvopharm.com, or via fax at 905-673-1842.

This page (OTCMKTS:MRVFF) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -